Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | CDC25A | P30304 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | PTEN | P60484 | 1/20 | 0.57 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.57 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | PTGFR | P43088 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70271 | 0.90 | KEAP1 (0.74) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL10290715 | 0.89 | SMN1; SMN2 (0.63) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL1206832 | 0.89 | KEAP1 (0.61) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| Hydrochloric Acid SCHEMBL10982620 | 0.88 | KEAP1 (0.71) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL7512732 | 0.87 | MAPT (0.62) | PPARGPTGFRHDAC3MAPK1ADRA1A | |
| SCHEMBL25170050 | 0.86 | MAPT (0.66) | PPARGPTGFRHDAC3MAPK1ADRA1A | |
| SCHEMBL7511756 | 0.86 | MMP12 (0.54) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL12329336 | 0.86 | MAPT (0.66) | PPARGPTGFRHDAC3MAPK1ADRA1A | |
| SCHEMBL289363 | 0.85 | KEAP1 (0.57) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL10750775 | 0.85 | ALDH1A1 (0.62) | KEAP1PTPRBCDC25ACDC25BPTEN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5238832-A | Lipoxygenase inhibitors | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1993-08-24 | — | — | US | claimed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20170158521-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2017-06-08 | — | — | US | disclosed |
| WO-2017017607-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| US-7858616-B2 | Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | PPARG, PPARD, PPARA | KEAP1 1877/4885PTPRB 1465/4885CDC25A 2055/4885 |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | KEAP1 2602/4885PTPRB 599/4885CDC25A 1648/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | KEAP1 311/4885PTPRB 2004/4885CDC25A 3050/4885 |
| US-20170158521-A1 | EMM-28, A NOVEL SYNTHETIC CRYSTALLINE MATERIAL, ITS PREPARATION AND USE | CD14, ERG28, DAP3 | KEAP1 4577/4885PTPRB 4067/4885CDC25A 245/4885 |
| US-20090197876-A1 | INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, ERBB2 | KEAP1 2468/4885PTPRB 469/4885CDC25A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.